Logotype for Dexcom Inc

Dexcom (DXCM) Q4 2018 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dexcom Inc

Q4 2018 earnings summary

4 Nov, 2026

Executive summary

  • FY18 revenue topped $1B for the first time, rising 44% YoY to $1,031.6M; U.S. revenue grew 37% and international revenue 74%.

  • G6 approval and launch, broader access efforts, and expanded manufacturing capacity supported growth; early G6 rollout also created operational challenges.

Financial highlights

  • FY18 gross profit was $663.9M, up from $492.1M; gross margin fell to 64% from 68%, reflecting channel and product mix, launches, and international expansion.

  • FY18 operating loss was $186.3M versus $42.5M; net loss was $127.1M versus $50.2M, and basic and diluted loss per share was $1.44 versus $0.58.

  • Q4 revenue was $338.0M and gross profit $222.8M; net loss was $179.7M, including the $217.7M Verily collaboration charge.

  • FY18 operating cash flow was $123.2M; cash, cash equivalents, and short-term marketable securities totaled $1,385.6M at year-end.

Outlook and guidance

  • Expanded Mesa manufacturing capacity was positioned to support broader G6 rollout, Medicare access targeted for late 2019, and preparation for G7, a fully disposable real-time CGM.

  • Growth opportunities include non-intensive Type 2 diabetes, gestational diabetes, and hospital monitoring; CGM penetration was viewed as low with substantial potential ahead.

  • Existing cash, projected commercial cash flows, and $195.6M available under the revolving credit facility were expected to cover liquidity needs for at least 12 months.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dexcom